Centre of Excellence for Translational Research in Asthma and Lung Disease, Institute of Genomics & Integrative Biology, Mall Road, Delhi University, Delhi 110054, India.
Tuberculosis (Edinb). 2011 Jan;91(1):67-70. doi: 10.1016/j.tube.2010.08.008. Epub 2010 Oct 13.
Inhaled therapies for pulmonary tuberculosis are in development and appear promising at first look. A fundamental premise of such therapy is efficient delivery of drug at high concentrations to the active disease site, while minimizing systemic delivery. This assumes that inhaled drug will actually reach the diseased lung, which while intuitive for healthy lungs, may be untrue for diseased lungs with abnormal structure or function. This review discusses the structural and functional aspects of respiratory physiology that are likely to impact local drug delivery and presents the available evidence on how this pertains to tuberculous lungs.
正在开发用于治疗肺结核的吸入疗法，从表面上看，这些疗法很有前景。这种治疗的一个基本前提是将药物高效地以高浓度递送到活跃的疾病部位，同时将全身递药减至最低。这假设吸入的药物实际上会到达患病的肺部，这对于健康的肺部来说是直观的，但对于结构或功能异常的患病肺部来说可能并不正确。这篇综述讨论了呼吸生理学的结构和功能方面，这些方面可能会影响局部药物输送，并介绍了关于这与结核性肺部相关的现有证据。
